Leslie Chinn is the Vice President of Clinical Pharmacology at HI-Bio. Leslie began her career as a Clinical Pharmacology Reviewer at the Food & Drug Administration supporting the Division of Antiviral Products. Following her time at the FDA, Leslie joined Genentech, where she led clinical pharmacology strategy and execution for numerous programs in non-oncology therapeutic areas. More recently, Leslie held roles at Equillium and at Principia Biopharma (prior to its acquisition by Sanofi) in which she led clinical pharmacology and translational efforts for all molecules within the portfolio.

Leslie received a BS in Biochemistry from the University of Michigan and a PhD in Pharmaceutical Sciences & Pharmacogenomics from the University of California San Francisco prior to completing postdoctoral training at the National Cancer Institute and the FDA.